| DOI: 10.29090/psa.2025.03.24.3617 | Pharm Sci Asia 2025; 52(3), 427-432 |
Incidence of bone marrow suppression and effectiveness of cervical cancer patients receiving concurrent chemoradiotherapyNatnicha Wilairat1, Chonlada Kacha1, Orapan Kaewchue2, Kanitta Thapsalid3, Siriporn Khambot3, Kwanjit Danwilai4*
1 Faculty of Pharmaceutical Sciences, Naresuan Univerisity, Thailand
2
Department of Obstetrics and Gynecology, Buddhachinaraj Hospital, Phitsanulok, Thailand
3
Department of Pharmacy, Buddhachinaraj Hospital, Phitsanulok, Thailand
4
Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Thailand
This study aims to determine the incidence of bone marrow suppression and the effectiveness of concurrent chemoradiotherapy (CCRT) in patients with cervical cancer. This retrospective study investigated cervical cancer patients who received CCRT between January 1, 2015, and December 31, 2018. We included patients aged ≥18 years with Stage IA2 to IVA adenocarcinoma or squamous cell carcinoma. Patients were excluded if they received neoadjuvant or adjuvant CCRT, myeloid growth factors, or erythropoietin within 28 days of the study, or had bone marrow disorders. The primary endpoint was the incidence of bone marrow suppression, with secondary endpoints of progression-free survival (PFS), overall survival (OS), and relative dose intensity (RDI). Descriptive statistics were used to analyze baseline characteristics, bone marrow suppression incidence, and RDI. OS and PFS were estimated using the Kaplan-Meier method. A total of 62 patients were included. The most common any-grade bone marrow suppression incidences were anemia (37.10%), thrombocytopenia (21%) and neutropenia (16.1%), respectively. The median PFS was 63.21 months (95% CI 56.66-69.77), the median OS was 69.25 months (95% CI 64.03-74.47), and RDI was 93.22% ± 7.93. Among cervical cancer patients received CCRT, anemia was the most common incidence of bone marrow suppression. The survival rates were remarkably high, accompanied a noticeably low recurrence rate.
Keyword:
Incidence; Effectiveness; Bone marrow suppression; Concurrent chemoradiotherapy; Cervical cancer
Download full paper (PDF File size: 623.53 KB.)
|
